Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ThromboGenics and BioInvent have completed the enrolment of 632-patient Phase IIb trial with anticoagulant TB-402 (factor VIII inhibitor) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery.
Subscribe to our email newsletter
The trial has recruited patients from 36 centers across Europe.
This double blind trial is comparing two doses of TB-402 (25mg and 50mg), given as a single intravenous infusion after total hip replacement, with the r factor Xa inhibitor rivaroxaban.
TB-402 partially inhibits factor VIII, a key component of the coagulation cascade.
ThromboGenics CEO Patrik De Haes said that VTE remains a significant unmet need in many clinical settings despite the introduction of a number of new anticoagulants.